Myostatin Inhibition Using ActRIIB-mFc Does Not Produce Weight Gain or Strength in the Nebulin Conditional KO Mouse

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Muscle Physiology

Background:

• Nemaline myopathy (NM) comprises congenital skeletal muscle diseases caused by mutations in at least 12 genes.
• NM presents with diverse clinical symptoms, including myofiber hypotrophy and characteristic cytoplasmic nemaline bodies.
• Previous research indicated potential benefits of myostatin inhibition in specific NM mouse models (Acta1 mutations).

Purpose of the Study:

• To investigate the efficacy of myostatin inhibition using ActRIIB-mFc in the nebulin conditional knockout (Neb cKO) mouse model of nemaline myopathy.
• To determine if myostatin inhibition impacts weight gain, muscle strength, myofiber size, or related signaling pathways in Neb cKO mice.

Main Methods:

• Administration of ActRIIB-mFc (a myostatin inhibitor) to Neb cKO mice.
• Assessment of physiological and molecular parameters including body weight, muscle strength, myofiber cross-sectional area, and hypertrophic signaling pathways.

Main Results:

• Treatment with ActRIIB-mFc did not lead to significant improvements in weight gain in Neb cKO mice.
• Myostatin inhibition failed to enhance muscle strength or increase myofiber size in this NM model.
• No discernible changes in hypertrophic pathway signaling were observed following ActRIIB-mFc treatment.

Conclusions:

• Nebulin conditional knockout mice with nemaline myopathy do not respond to myostatin inhibition.
• The lack of response in Neb cKO mice contrasts with the benefits observed in other nemaline myopathy models, highlighting genetic specificity.
• These findings suggest that therapeutic strategies targeting myostatin may not be universally effective across all genetic subtypes of nemaline myopathy.